{"id":"mrna-1010","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"This mRNA vaccine is designed to be personalized for each patient based on their tumor's unique mutation profile. It encodes multiple neoantigens derived from the patient's own cancer, which are presented to the immune system to generate CD8+ and CD4+ T-cell responses against tumor-specific mutations. The approach aims to enhance anti-tumor immunity and reduce recurrence risk.","oneSentence":"mRNA-1010 is a therapeutic cancer vaccine that encodes personalized tumor-associated neoantigens to stimulate the patient's immune system to recognize and attack cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:14.182Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Melanoma (adjuvant setting, in combination with Merck's Keytruda)"},{"name":"Non-small cell lung cancer (adjuvant setting, in combination with checkpoint inhibitor)"}]},"trialDetails":[{"nctId":"NCT05397223","phase":"PHASE1","title":"A Study of Modified mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-24","conditions":"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus","enrollment":308},{"nctId":"NCT05606965","phase":"PHASE2","title":"A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-11-02","conditions":"Influenza","enrollment":172},{"nctId":"NCT06602024","phase":"PHASE3","title":"A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-09-16","conditions":"Seasonal Influenza","enrollment":40817},{"nctId":"NCT05827978","phase":"PHASE3","title":"Study of mRNA-1010 Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-17","conditions":"Seasonal Influenza","enrollment":8411},{"nctId":"NCT05827068","phase":"PHASE1, PHASE2","title":"A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-03-27","conditions":"Seasonal Influenza","enrollment":698},{"nctId":"NCT05566639","phase":"PHASE3","title":"A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-09-14","conditions":"Seasonal Influenza","enrollment":22502},{"nctId":"NCT05868382","phase":"PHASE2","title":"Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-05-15","conditions":"Influenza","enrollment":270},{"nctId":"NCT05415462","phase":"PHASE3","title":"A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-06-06","conditions":"Seasonal Influenza","enrollment":6102},{"nctId":"NCT05585632","phase":"PHASE1","title":"A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-10-14","conditions":"SARS-CoV-2, Influenza, RSV","enrollment":392},{"nctId":"NCT05375838","phase":"PHASE1, PHASE2","title":"A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-13","conditions":"SARS-CoV-2, Influenza","enrollment":550},{"nctId":"NCT05333289","phase":"PHASE1, PHASE2","title":"A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-04-06","conditions":"Seasonal Influenza","enrollment":572},{"nctId":"NCT04956575","phase":"PHASE1, PHASE2","title":"A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2021-07-06","conditions":"Seasonal Influenza","enrollment":885}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Seasonal influenza vaccine"],"phase":"phase_3","status":"active","brandName":"mRNA-1010","genericName":"mRNA-1010","companyName":"ModernaTX, Inc.","companyId":"modernatx-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"mRNA-1010 is a therapeutic cancer vaccine that encodes personalized tumor-associated neoantigens to stimulate the patient's immune system to recognize and attack cancer cells. Used for Melanoma (adjuvant setting, in combination with Merck's Keytruda), Non-small cell lung cancer (adjuvant setting, in combination with checkpoint inhibitor).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}